Parallel cultivates, produces, and processes cannabis for medical purposes.
Parallel cultivates, produces, and processes cannabis for medical purposes. It also operates a marijuana dispensary. The company's mission is to provide the safest, highest quality cannabis-based products that empower health and enable them to live well.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 8, 2022 | Debt Financing | $10M | 1 |
![]() |
— | Detail |
Jan 1, 2021 | Series Unknown | — | 1 | — | — | Detail |
Jun 27, 2019 | Series D | $100M | 1 |
![]() |
— | Detail |
Apr 13, 2019 | Debt Financing | $165.42M | — | — | — | Detail |
Aug 6, 2018 | Series C | $65M | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jan 25, 2022
![]() |
Seed | $4.50M | Cryptocurrency | — |
Aug 7, 2020
![]() |
Grant | $3M | Education | Yes |
Nov 13, 2019
![]() |
Series Unknown | $1.08M | Cannabis | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Debt Financing |
![]() |
Yes | Series D |
![]() |
— | Series Unknown |
Parallel has acquired 3 organizations. Their most recent acquisition was New England Treatment Access on Jan 14, 2019. They acquired New England Treatment Access for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jan 14, 2019
![]() |
Alternative Medicine | acquisition | — | Detail |
Jun 25, 2019
![]() |
Biopharma | acquisition | — | Detail |
Apr 1, 2021
![]() |
Fitness | acquisition | — | Detail |